Dose-sparing romidepsin regimen promising in cutaneous T-cell lymphoma
medwireNews: Patients with cutaneous T-cell lymphoma (CTCL) who respond to the standard romidepsin dosing regimen could benefit from transitioning to a dose-sparing schedule, suggests a case series published in JAMA Oncology.
The histone deacetylase inhibitor is usually administered via infusions on days 1, 8 and 15 of a 28-day cycle. But patients who responded to standard therapy could be switched to a reduced dosing schedule – once every other week and eventually to once a month – at the physician’s discretion.
Of 38 patients with mycosis fungoides or Sézary syndrome included in this medical review, 17 received romidepsin for longer than 6 months, with a median duration of treatment exposure of 15 months, report Joan Guitart (Northwestern University, Chicago, Illinois, USA) and co-workers.
Nine of these long-term responders received the dose-sparing regimen, with three patients achieving complete remission and the remaining six attaining a partial response.
This approach “allows for maintaining response, tolerability, and convenience”, say the researchers, adding that it “may offer a new option to prolong response in a disease notorious for short responses.”
But they conclude that the results need validation in prospective trials.
medwireNews is an independent medical news service provided by Springer Healthcare Limited. © Springer Healthcare Ltd; 2016